FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Brookfield Medical Hit with GMP Untitled Letter

FDA posts an untitled letter sent to Brookfield Medical/Surgical Supplies due to GMP issues cited in a May inspection.

latest-news-card-1
Human Drugs

Unicycive Therapeutics NDA for Oxylanthanum

FDA accepts for review a Unicycive Therapeutics 505 (b) (2) NDA for oxylanthanum carbonate and its use in treating hyperphosphatemia patients with chr...

latest-news-card-1
Medical Devices

FDA Clears Vertiwedge Intraosseous Device

FDA clears a Foundation Surgical 510(k) for its Vertiwedge Intraosseous, a motion-sparing partial vertebral body replacement device.

latest-news-card-1
Human Drugs

Group Criticizes FDA Foot Dragging on Phenylephrine

Advocacy group Public Citizen criticizes FDA for dragging its feet in removing phenylephrine from the U.S. market.

latest-news-card-1
Human Drugs

Dizal NDA for Lung Cancer Drug

Dizal Pharmaceutical submits an NDA for sunvozertinib for treating locally advanced or metastatic non-small cell lung cancer.

latest-news-card-1
Human Drugs

Neurotech Review Extension on Retinal Disease BLA

FDA extends its review of a Neurotech Pharmaceuticals BLA for NT-501 (revakinagene taroretcel) as a treatment for macular telangiectasia Type 2.

latest-news-card-1
Biologics

Darxalex Faspro sBLA for Smoldering Multiple Myeloma

Johnson & Johnson files a supplemental BLA for Darzalex Faspro (daratumumab and hyaluronidase-fihj) and its use for treating adult patients with high-...

latest-news-card-1
Medical Devices

Bayers Medrad Centargo CT Injection Cleared

FDA clears a Bayer 510(k) for its Medrad Centargo CT Injection System, a multi-patient injector for use in computed tomography.

latest-news-card-1
Human Drugs

Allogene Reports Encouraging CAR-T Therapy Data

Allogene Therapeutics reports encouraging response rate data for its investigational ALLO-316 in advanced renal cell carcinoma, but the results also s...

latest-news-card-1
Human Drugs

Model-Informed Drug Development Comments

Four stakeholders respond to an FDA request for comments on guidance development and engaging with stakeholders on model-informed drug development.